The Intraocular Melanoma Treatment Market is being shaped by the need to control tumors while preserving the eye and, where possible, useful vision. Uveal melanoma treatment has traditionally relied on local therapies, but advances in radiation techniques and systemic medicines are gradually broadening the range of options available to patients.

Plaque brachytherapy remains a widely used approach for suitable small and medium-sized tumors because it can provide strong local control while allowing the eye to be preserved. Proton beam radiotherapy is another important option, particularly when tumor location or anatomy makes other approaches less suitable.

A major area of market development is metastatic disease, where treatment needs remain substantial. Tebentafusp has changed the treatment landscape for eligible HLA-A*02:01-positive patients, while researchers are investigating targeted therapies, immune-based combinations, and liver-directed treatments for patients whose disease spreads beyond the eye.

Future growth is likely to depend on therapies that can improve long-term outcomes without sacrificing ocular function. Clinical research into neoadjuvant tebentafusp, adjuvant strategies, and new molecular targets suggests that the market could gradually move toward more personalized treatment plans based on tumor biology and individual patient characteristics.